With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Investigating the Role of Circadian Rhythm in the Progression of Acute Myeloid Leukemia||Boston Children's Hospital / Samantha Morris, PhD||Young Investigator Grants||2013||Massachusetts|
|Histone Modification and Hmgn1 Overexpression as Drivers of B-ALL with Polysomy 21||Dana-Farber Cancer Institute / Andrew Lane, MD, PhD||Young Investigator Grants||2013||Massachusetts|
|Oncogenic Hedgehog Pathway Activation by a Putative Rho GTPase-Activating Protein||Lucile Packard Children's Hospital at Stanford University School of Medicine / Jun Ni, PhD||Young Investigator Grants||2013||California|
|Epigenetic Regulation of T cell Activation and Immunotherapy||The Johns Hopkins University School of Medicine / Brian Ladle, MD, PhD||Young Investigator Grants||2013||Maryland|
|Genetic Dissection of Trisomy 21-TMD Using Human Pluripotent Stem Cells||Boston Children's Hospital / Glenn MacLean||Young Investigator Grants||2013||Massachusetts|
|Genetic Alterations in Intramedullary Spinal Cord Tumors||The Johns Hopkins University School of Medicine / George Jallo, MD||Innovation Grants||2013||Maryland|
|Nanoparticle Delivery of Therapeutic Agents in Neuroblastomas||Children's Hospital of Philadelphia / Garrett M. Brodeur, MD||Innovation Grants||2013||Pennsylvania|
|Reactivating Apoptosis in Refractory Pediatric Cancer by Molecular Inhibition of MCL-1||Dana-Farber Cancer Institute / Loren Walensky, MD, PhD||Innovation Grants||2013||Massachusetts|
|Identification of TFAP4 (Transcription Factor AP-4/Activating Enhancer Binding Protein) as a Potential Master Regulator/Synthetic Lethal Gene of MYCN Amplified Neuroblastoma||Columbia University Medical Center / Darrell Yamashiro, MD, PhD||Innovation Grants||2013||New York|
|Therapeutic Potential of the MST1/Hippo Tumor Suppressor Pathway in Alveolar Rhabdomyosarcoma||Duke University / Corinne Mary Linardic, MD, PhD||Innovation Grants||2013||North Carolina|